Soleus Capital Management has significantly increased its stake in Vericel (NASDAQ:VCEL), acquiring 1,785,079 shares valued at approximately $63.40 million during the first quarter. This move brings Soleus’s total holdings in Vericel to 2,549,079 shares, worth $82 million, reflecting a quarter-end value increase of $54.49 million due to both new purchases and rising stock prices.

Despite Vericel’s stock declining about 20% over the past year, the company has demonstrated robust operational growth, posting a 20% year-over-year revenue increase to $63.2 million, largely driven by its MACI cartilage repair therapy. With a gross margin expansion to 74% and a doubling of adjusted EBITDA, Vericel is positioning itself for sustained growth, especially following FDA clearance for a Phase 3 study of MACI for ankle cartilage defects.

For market professionals, Soleus’s aggressive buy suggests confidence in Vericel’s long-term growth trajectory, despite recent stock performance. This could indicate a buying opportunity for investors looking to capitalize on potential rebounds in the biopharmaceutical sector.

Source: nasdaq.com